

**ÆTERNA ZENTARIS INC.
IS A LATE-STAGE,
PURE PLAY GLOBAL
BIOPHARMACEUTICAL
COMPANY FOCUSED ON
ENDOCRINE THERAPY
AND ONCOLOGY, WITH
PROVEN EXPERTISE IN DRUG
DISCOVERY, DEVELOPMENT
AND COMMERCIALIZATION**





COMPANY STRENGTHS

- Depth** Deep and focused pipeline at all stages of development
- Breadth** Ability to penetrate large and growing markets
- Execution** Successful achievement of clinical and corporate milestones

ÆTERNA ZENTARIS INC.
(TSX: AEZ, NASDAQ: AEZS)

Please note
that all amounts are in US dollars

2006 HIGHLIGHTS

In 2006, Æterna Zentaris
delivered solid results

LATE-STAGE PROGRAMS

CETRORELIX

- ▶ Acceptance by FDA of IND for Phase 3 program in benign prostatic hyperplasia (BPH)
- ▶ Launch of Cetrotide® (cetorelix) in Japan for *in vitro* fertilization
- ▶ Regained exclusive worldwide (ex-Japan) rights for cetorelix in BPH

OZARELIX

- ▶ Positive Phase 2 results in BPH
Initiation of Phase 2b trial
- ▶ Positive Phase 2 results in prostate cancer
Initiation of Phase 2b trial
- ▶ Exclusive license granted to Nippon Kayaku for ozarelix in oncology in Japan

PERIFOSINE

- ▶ Positive interim Phase 2 data in advanced renal cell carcinoma
- ▶ Positive Phase 2 results in multiple cancers
- ▶ Initiation of multiple Phase 1 and Phase 2 trials in cancer

EARLIER-STAGE PROGRAMS

AN-152

- ▶ Positive top line Phase 1 results for breast and gynaecological cancers

ZEN-012

- ▶ Acceptance by FDA of IND for Phase 1 trial in solid tumors and lymphoma

PURE PLAY CORPORATE STRATEGY

Æterna Zentaris spins off subsidiary Atrium and emerges as a pure play biopharmaceutical company

- ▶ Secondary offering ensuring financial stability to execute business plan
- ▶ Distribution of remaining Atrium shares to Æterna Zentaris shareholders

